Ocugen (OCGN) Research & Development (2014 - 2026)

Ocugen has reported Research & Development for 13 years, with the latest figure at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 18.11% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $41.5 million (up 19.08% YoY), and the FY2025 full-year result was $39.8 million, up 23.73% from the prior year.
• Research & Development for Q1 2026 stood at $11.3 million, up from $10.7 million in the prior quarter.
• The five-year high for Research & Development was $17.9 million in Q3 2022, with the low at $6.8 million in Q1 2024.
• Historically, Research & Development has averaged $10.5 million across 5 years, with a median of $9.5 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development soared 227.05% — and 2023, when it slumped 60.71%.
• Ocugen's Research & Development stood at $17.2 million in 2022, then slumped by 54.84% to $7.8 million in 2023, then grew by 6.57% to $8.3 million in 2024, then advanced by 28.7% to $10.7 million in 2025, then rose by 5.49% to $11.3 million in 2026.
• The last three Research & Development figures came in at $11.3 million (Q1 2026), $10.7 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.